The Relationship Between Vitamin D Status and HIV-related Complications in HIV-infected Children and Young Adults

Allison Ross Eckard, Emory University
Vin Tangpricha, Emory University
Shabnam Seydafekan, Emory University
Mary Ann O’Riordan, Case Western Reserve University
Norma Storer, Case Western Reserve University
Danielle Labbato, Case Western Reserve University
Grace A. McComsey, Case Western Reserve University

Journal Title: Pediatric Infectious Disease Journal
Volume: Volume 32, Number 11
Publisher: Lippincott, Williams & Wilkins | 2013-11-01, Pages 1224-1229
Type of Work: Article | Post-print: After Peer Review
Publisher DOI: 10.1097/INF.0b013e318286c793
Permanent URL: https://pid.emory.edu/ark:/25593/twx8h

Final published version: http://dx.doi.org/10.1097/INF.0b013e318286c793

Copyright information:
Copyright © 2013 by Lippincott Williams & Wilkins.

Accessed January 21, 2020 3:20 PM EST
The Relationship between Vitamin D Status and HIV-Related Complications in HIV-infected Children and Young Adults

Allison Ross Eckard, MD1,2, Vin Tangpricha, MD, PhD1, Shabnam Seydafkan, MD1, Mary O’Riordan, MS3, Norma Storer, RN3, Danielle Labbato, RN3, and Grace A. McComsey, MD3

1Emory University School of Medicine, Atlanta, GA, USA
2Children’s Healthcare of Atlanta, Atlanta, GA, USA
3Case Western Reserve University and Rainbow Babies & Children’s Hospital, Cleveland, OH, USA

Abstract

Background—In HIV-infected adults, we and others have shown that vitamin D deficiency is independently associated with increased carotid intima-media thickness (cIMT), a surrogate marker for cardiovascular disease (CVD). This study explored for the first time the relationship between vitamin D and CVD risk in HIV-infected youth.

Methods—This is a cross-sectional assessment of cIMT, inflammation, metabolic markers and vitamin D status in HIV-infected youth and healthy controls. We measured serum 25-hydroxyvitamin D (25(OH)D), fasting lipids, insulin, glucose, inflammatory markers, and cIMT.

Results—30 HIV–infected subjects and 31 controls were included. Among HIV-infected subjects, median age was 11 years (37% males; 73% black; similar to controls). HIV-infected subjects’ mean (standard deviation) serum 25(OH)D was 24 (35) ng/mL; 70% had 25(OH)D <20 ng/mL (deficient), 23% between 20–30 ng/mL (insufficient), and 7% >30 ng/mL (sufficient); proportions were similar to controls (P=0.17). After adjusting for season, sex and race, there was no difference in serum 25(OH)D between groups (P=0.11). Serum 25(OH)D was not significantly correlated with cIMT, inflammatory markers, or lipids. Serum 25(OH)D was negatively correlated with body mass index, insulin resistance, HIV duration, and cumulative use of antiretroviral therapy, non- and nucleoside reverse transcriptase inhibitors.

Conclusions—Most HIV-infected youth have vitamin D deficiency or insufficiency. Despite no direct association between serum 25(OH)D and cIMT, there were notable associations with some CVD risk factors, particularly inverse correlation with insulin resistance. Studies are needed to determine whether CVD risk, including insulin resistance, could be improved with vitamin D supplementation.

Keywords

HIV; children and adolescents; vitamin D deficiency; cardiovascular disease; insulin resistance
HIV infection independently increases the risk of developing cardiovascular disease (CVD).\textsuperscript{1,2} This increased risk is likely multi-factorial, including contributions from traditional risk factors, as well as HIV-related factors such as increased inflammation and antiretroviral therapy (ART).\textsuperscript{3–7} In the general population, vitamin D deficiency has been shown to be associated with a number of physiologic and pathophysiologic processes known to increase CVD risk, such as obesity, hypertension, diabetes and insulin resistance, exercise capacity, and increased inflammation.\textsuperscript{8–14} Likewise, vitamin D deficiency is associated with worse arterial compliance\textsuperscript{15} and increased carotid intima-media thickness (cIMT),\textsuperscript{16} both surrogate markers for CVD. Proposed mechanisms of vitamin D’s role in CVD include its effects on the renin-angiotensin system,\textsuperscript{17} on glycemic control,\textsuperscript{18} and on inflammatory cytokines,\textsuperscript{9} and/or its direct effects on the vasculature.\textsuperscript{19}

The prevalence of vitamin D deficiency, as measured by blood concentrations of 25-hydroxyvitamin D (25(OH)D; the established marker of overall vitamin D status),\textsuperscript{20} is very high in the HIV-infected population, including in HIV-infected youth.\textsuperscript{21–23} A number of cross-sectional studies have also found increased carotid IMT in HIV-infected children and young adults compared to healthy controls,\textsuperscript{24–27} suggesting that this population is at an increased risk of CVD similar to their adult counterparts. However, it is unknown how vitamin D status affects cIMT, inflammation, and CVD risk in this population, despite data that suggests that vitamin D status affects cIMT in the HIV-infected adult population.\textsuperscript{21,28} Demonstrating significant relationships between vitamin D status and markers of CVD risk would suggest that correcting vitamin D deficiency could offer a potentially inexpensive strategy to attenuate risk and help to optimize health. Thus, the purpose of this study was to 1) to examine vitamin D status among HIV+ subjects and healthy controls, 2) to determine the relationship of serum 25(OH)D with carotid IMT in HIV+ children and young adults, and 3) to investigate the relationship of serum 25(OH)D with both traditional and HIV-related CVD risk factors, including inflammation.

METHODS

Study design/population

This study is a cross-sectional analysis from a prospective, longitudinal, observational cohort study evaluating carotid IMT in HIV-infected youth and healthy uninfected controls. As previously described,\textsuperscript{25,29} HIV-infected children and young adults attending the HIV clinic at University Hospitals Case Medical Center, Cleveland, Ohio were eligible for enrollment. Inclusion criteria were HIV infection and age 2–21 years. Exclusion criteria included active opportunistic infections, renal failure, diabetes, hypertension, family history of premature CVD, and smoking. All HIV-infected children and young adults between 2–21 years old were eligible and enrolled into the original cohort study.

Healthy controls were chosen randomly from a larger convenience sample including children of hospital staff, siblings of HIV-infected patients, and patients seen at the general pediatric clinic. The goal was to achieve a group with similar age (±2 years), body mass index (BMI) (±1 kg/m\textsuperscript{2}), and proportions of sex and race. Matching used for selection was not retained in the analysis. Additional exclusion criteria for uninfected controls included current or recent infectious or inflammatory illness, known chronic disease, and receiving any prescription medication. None of the controls had a prior history of perinatal HIV exposure or received any antiretrovirals \textit{in utero} or after birth.

Stored serum was utilized for analysis and all subjects with an available sample from any time point were included in this cross-sectional, \textit{post hoc} analysis. Measurements associated with a particular sample were used for each subject.
The study was reviewed and approved by the Institutional Review Board of the University Hospitals Case Medical Center. All parents or legal guardians and children, when appropriate, gave written informed consent to participate in the study.

Clinical assessments

Standardized blood pressure measurements and anthropometry were performed by the same experienced study coordinator (NS). Anthropometric measurements were performed based on procedure recommendations from the Metabolic Study Group of the AIDS Clinical Trials Group, which included waist and hip circumference obtained at the level of the umbilicus and at the widest portion of the buttocks, respectively. Weight and height measurements were obtained in all subjects from the same clinic scale, and blood pressure was obtained with an automated, calibrated blood pressure machine. An extensive chart review of HIV-infected subjects included demographics, all past and current medical diagnoses, concomitant medications, and detailed ART history. Controls (or guardians) completed questionnaires in order to obtain their relevant demographic and medical information.

Laboratory tests

Fasting blood (≥8 hours) was drawn from all subjects for real-time measurements of insulin, glucose, and lipoprotein profile. Insulin resistance was calculated using the homeostasis model assessment of insulin resistance (HOMA-IR) (fasting insulin (μU/ml) x fasting glucose (mg/dl)/405.30 Absolute and percent CD4+ T-cell count and serum HIV-1 RNA level were concomitantly measured in the HIV-infected group as markers of HIV disease activity.

Serum concentrations of 25(OH)D were measured as the best determinant of vitamin D status.20 All samples were analyzed in the same co-investigator’s laboratory (VT) at Emory University by an experienced technician (SS). Concentrations of 25(OH)D were assessed using specific ELISA kits (IDS, LTD, Fountain Hills, AZ, USA) as per the manufacturer’s product manual and tested in duplicate. Median intra-assay and inter-assay coefficients of variation (CV) were <12%. Quality control was ensured by participation in the vitamin D external quality assessment scheme (DEQAS, site 606). Laboratory personnel were blinded to clinical information. We adopted the current Endocrine Society’s and Institute of Medicine’s (IOM) guidelines defining vitamin D deficiency as serum 25(OH)D concentrations <20 ng/mL.31,32 We also further defined serum 25(OH)D concentrations ≥20–29 ng/mL as vitamin D insufficiency and serum 25(OH)D concentrations >29 ng/mL as optimal vitamin D status, as per the Endocrine Society guidelines.31

We selected biomarkers known to be associated with heightened CVD risk and to be elevated in HIV-infected patients.33–36 Tumor necrosis factor (TNF)-α, soluble tumor necrosis factor receptor-I (sTNFR-I), soluble tumor necrosis factor receptor-II (sTNFR-II), interleukin-6 (IL-6), high sensitivity C-reactive protein (hsCRP), soluble intercellular adhesion molecule-1 (sICAM-1), and soluble vascular cellular adhesion molecule-1 (sVCAM-1) were measured using an enzyme-labeled immunosorbent sandwich assay (AushonBiosystems, Billerica, Massachusetts, USA). The median intra-assay coefficients of variation for TNF-a, sTNFR-I, sTNFR-II, IL-6, hsCRP, vWF, sICAM-1, sVCAM-1, and MPO were 14.5%, 8.8%, 8.6%, 11.7%, 6.9%, 13.3%, 8.0%, 8.7%, and 7.5%, respectively. The median interassay coefficients of variation for each assay were 9.8%, 10.8%, 6.0%, 10.4%, 4.5%, 9.0%, 4.2%, 13.4%, and 12.6%, respectively.

Carotid IMT measurements

All carotid ultrasounds were performed by an experienced sonographer and read by an experienced radiologist, both blinded to HIV status. Carotid IMT methods were used as
Briefly, images of the bilateral common carotid artery (CCA) and internal carotid artery (ICA) were obtained in longitudinal views separately. Images of the near (proximal) and far (distal) wall free of plaques were acquired with a 7–14 MHz AT 1204 linear array transducer (Toshiba American Medical Systems, Tustin, California) operating at 14 MHz with differential harmonics. Three measurements of IMT were obtained at near and far wall of each CCA and ICA. The mean of three measurements at each site (right and left side) was used as final measurement of IMT for that site (for both CCA and ICA, the far and near wall had three IMT measurements each, resulting in a total of 12 measurements per subject). Right and left sides were then averaged, and reported as a single ICA and CCA measurement.

### Statistical methods

Demographics, clinical characteristics and fasting metabolic parameters are described by study group, and HIV-related characteristics are described for HIV-infected subjects. HIV-infected subjects were compared to the controls for all variables of interest. For between-group comparisons, nominal variables were compared using $\chi^2$ analysis or Fisher’s exact test. Continuous measures were tested for normality. Normally-distributed variables were compared using t-tests, and non-normally distributed variables were compared using Wilcoxon rank sum tests. Serum 25(OH)D concentrations were compared between groups using both ordinal categories based on vitamin D status (i.e. deficient, insufficient and sufficient) and by continuous measures. ANCOVA was then used on continuous measures of serum 25(OH)D concentrations to compare $P$ values between unadjusted means and means adjusted for sex, race, and season of blood draw.

The relationships of 25(OH)D to the other variables of interest were estimated separately for the HIV-infected group and the controls with Spearman Rank Correlation Coefficients. Variables with $P < 0.05$ in the univariate analysis among the HIV-infected subjects were then included in a multiple linear regression model using a forward selection process. $P \leq 0.50$ was used as the limit for inclusion in the final model.

All analyses were performed using SAS, version 9.2 (SAS Institute, Cary, North Carolina). The level of significance was set at 0.05.

### RESULTS

#### Study Population and Comparison between Groups

Thirty HIV-infected subjects and 31 controls were included in the analysis. Table 1 describes the demographic, clinical, and laboratory characteristics for both groups. Median age in the HIV-infected group was 12.5 years with 37% male and 81% black. Seventy-seven percent of HIV-infected subjects had their blood drawn in either winter or spring seasons. Ten of the HIV-infected subjects were taking vitamin D supplements or multivitamins that contained 200–400 IU/day of vitamin D, while none of the controls were taking dietary supplements. There were no smokers in either group.

Table 2 describes HIV-specific characteristics. None of the subjects had any co-morbid conditions or were taking any medications which could affect the results. All of the subjects who were on an non-nucleoside reverse transcriptase inhibitor (NNRTI) at the time of the analysis were on efavirenz except one. Three subjects had lipodystrophy.

Age, male sex, race, BMI, blood pressure, and season of blood draw were similar between groups. Total cholesterol, high-density lipoprotein cholesterol, and HOMA-IR were also similar between groups, but triglycerides were higher in the HIV-infected group. Tumor necrosis factors, its soluble receptors, and IL-6 were similar between groups, but hCRP,
sICAM-1 and sVCAM-1 were higher in the HIV-infected group. Both CCA and ICA IMT were similar between groups.

**Vitamin D Status in HIV-infected Subjects and Healthy Controls**

The proportion of subjects by study group in each category of vitamin D status based on their serum 25(OH)D concentrations is presented in Figure 1. The proportion of subjects in each category was similar for both groups, but the overwhelming majority of subjects in both groups were in the vitamin D deficient range.

The unadjusted mean (standard deviation, SD) was 24 (35) ng/mL in the HIV-infected group versus 14 (5) ng/ml in the control group (P = 0.07). After adjusting for season, sex and race, there was still no difference in 25(OH)D between groups (P=0.11). One HIV-infected subject was inadvertently taking mega-doses of vitamin D and had a 25(OH)D concentration of 204 ng/mL, which accounts for the high SD in the HIV-infected group. Excluding this subject in the analysis did not change the overall significance of the results.

**Relationship Between 25(OH)D and CVD Risk Factors, Inflammation and HIV-Related Factors**

Serum 25-hydroxyvitamin D was negatively correlated with BMI in both the HIV-infected subjects and healthy controls, while it was only negatively correlated with age among the controls (Table 3). Among controls, serum 25(OH)D was also positively correlated with sTNFR-II and sICAM-1 and negatively correlated with CCA IMT. Within the HIV-infected group, 25(OH)D was negatively correlated with HOMA-IR, HIV duration, and cumulative duration of ART, NRTI, and NNRTI duration.

In the multiple linear regression model, the very high outlying value described earlier was excluded from the analysis to prevent an extreme departure from normality. Four variables remained in the final model, including duration of HIV (P < 0.01), HOMA-IR (P = 0.09), duration of NNRTI (P = 0.25) and age (P = 0.50).

**DISCUSSION**

In this study, we investigated the relationship between vitamin D status, CVD risk factors and vascular disease (cIMT) in HIV-infected children and young adults. In contrast to similar studies in HIV-infected adults, we did not detect any significant associations between vitamin D status and cIMT with the HIV-infected group. However, there were notable significant correlations between low vitamin D and several well-established CVD risk factors, including insulin resistance and higher BMI. In addition, we demonstrated significant correlations between low vitamin D and HIV-related factors, including longer duration of HIV disease and cumulative use of ART, NRTI, and NNRTI. There were no significant correlations within the HIV-infected group between serum 25(OH)D and CD4 count, inflammation markers, and lipids.

Importantly, there was a very high prevalence of vitamin D deficiency and insufficiency. In fact, 72% and 87% of the HIV-infected subjects and healthy controls, respectively, were deficient as per both the current Endocrine Society and IOM guidelines. Moreover, 93% and 100% of the HIV-infected subjects and healthy controls, respectively, had vitamin D deficiency or insufficiency per the current Endocrine Society Guidelines. Albeit striking, these numbers are consistent with other studies of HIV-infected youth in other geographical regions, suggesting the generalizability of these current data. These data underscore the need to investigate the appropriate supplementation dose and adequate blood concentration of 25(OH)D in HIV-infected youth with the ultimate goal of developing population-specific guidelines. The findings of this study suggest that vitamin D deficiency is common and
randomized-controlled trials are needed to determine if vitamin D supplementation has a positive impact on CVD risk factors.

We have previously shown a relationship between vitamin D status and CVD in ART-stable, HIV-infected adults, where an independent association was observed between vitamin D status and carotid IMT. Notably, subjects with CCA IMT levels above the median were 10-fold more likely to have the lowest 25(OH)D concentrations. Vitamin D status was also associated with the inflammatory and endothelial activation markers, sTNFR-1 and sICAM-1, both shown to be associated with CVD and atherosclerosis development in the general population. In this current study investigating HIV-infected children and young adults, we observed a similar relationship within the control group but not within the HIV-infected group. This may be due to the fact that the HIV-infected group had additional HIV-related confounders that neither the controls nor the previously-studied adults had, as not all of the HIV-infected subjects in our current study were virologically-suppressed. This relationship deserves further investigation in larger, prospective trials of virologically-suppressed HIV-infected children and young adults.

In univariate analysis, HOMA-IR was significantly associated with 25(OH)D among the HIV-infected group. While this relationship did not remain significant in the regression analysis, these results must be interpreted with caution as we explored a large number of variables given our small number of subjects, and this potential link deserves further investigation. The association of vitamin D status and diabetes was reviewed recently in a meta-analysis of 28 independently published studies and showed a significant 55% reduction in the risk of diabetes in the general population.

Insulin resistance and diabetes are very well-described disorders among HIV-infected individuals. In ART-treated HIV-infected men, the risk of diabetes is 4-fold higher than healthy controls without HIV. The prevalence of impaired glucose homeostasis in HIV-infected children ranges from about 8–35%, and most commonly manifests itself as insulin resistance. Insulin resistance in the HIV population is a common component of lipodystrophy and metabolic syndrome, complications of HIV infection and ART. In HIV-infected adults, there are a few pharmacologic interventions that have been shown to improve insulin resistance associated with these conditions, including thiazolidinediones and metformin. While metformin is approved for children ≥10 years of age with type 2 diabetes, it has not been tested in HIV-infected children as a means of improving insulin resistance in individuals who do not have frank diabetes.

Thus, there are currently few options in the HIV-infected pediatric population for improving insulin resistance, and the CVD risk associated with it, other than diet and exercise. There are some antiretroviral medications which are less likely to cause insulin resistance than others; however, choices are very limited in children due to inadequate weight to take the doses in the pills on the market and/or inability to swallow pills for medications that are not available in liquid formulations. Similarly, it is necessary in some cases of perinatally-infected young adults to return to older antiretrovirals with more toxic metabolic profiles due extensive viral resistance that prohibits the use of newer drugs and drug classes. If raising serum 25(OH)D concentrations in HIV-infected children and young adults improves insulin resistance, this would offer a potential adjuvant treatment that is inexpensive and safe.

In HIV-infected adults, vitamin D supplementation has actually been associated with decreasing insulin sensitivity; however, these effects warrant investigation specifically in the pediatric population, as data from adult studies cannot be automatically extrapolated. Moreover, in Longenecker, et al, 12 weeks of 4,000 IU/daily of vitamin D supplementation...
vitamin D supplementation not only worsened insulin resistance but also did not improve endothelial function. However, this supplementation dose was inadequate to increase serum concentrations to optimal levels and was a relatively short follow-up period. Thus, further studies are needed to better evaluate any changes in insulin resistance and surrogate CVD markers that may occur with adequate vitamin D repletion doses before any definitive conclusions can be made.

While vitamin D has long been known to play a major role in bone metabolism, over the last few years, it has become clear that vitamin D has many non-classic, but vital functions in almost every tissue of the body, including those that regulate glucose metabolism. Studies from the adult general population show that there is a higher prevalence of type 2 diabetes in individuals with vitamin D deficiency, and a similar association has been described in HIV-infected adults. Prevention of type 1 diabetes has been demonstrated in animals exposed to high doses of the active form of vitamin D, 1,25-dihydroxyvitamin D (1,25(OH)₂D) which acts as a steroid hormone by binding to the nuclear vitamin D receptor (VDR) and regulating transcription of hundreds of genes. To date, >900 regulated genes have been identified. In the case of glucose metabolism, 1,25(OH)₂D has been shown to bind to the VDR on the pancreatic beta cells. Based on these epidemiologic and preclinical data, further studies investigating the relationship between vitamin D and insulin resistance in the HIV-infected population are warranted.

In addition to a negative correlation between serum 25(OH)D and insulin resistance within the HIV-infected group, we demonstrated similar relationships between serum 25(OH)D and BMI, HIV duration, and ART duration. Studies demonstrate that certain antiretrovirals, such as efavirenz and ritonavir, interfere with vitamin D metabolism. Similarly, obesity increases the likelihood of vitamin D deficiency because a greater amount of synthesized 25(OH)D is deposited in fat tissue. These data emphasize the importance of conducting population-specific research trials within this unique population, especially given the high prevalence of vitamin D deficiency demonstrated among HIV-infected children and young adults in this study and others. With the growing obesity issue in industrialized countries, HIV-infected children’s life-long need for ART, and HIV/ART’s associated metabolic complications, trials are needed to further define the role that vitamin D plays, the impact of improving blood concentrations of 25(OH)D, and what doses are needed to restore and maintain vitamin D status.

Despite the novel data presented, there are limitations to this study. As an exploratory study, this study was not powered and investigated a number of associations between 25(OH)D and variables of interest. Thus, this limits the overall interpretation of the data. Likewise, as a cross-sectional design, the associations demonstrated cannot prove causality. Additionally, there were a relatively small number of subjects which may have limited our ability to detect relationships with serum 25(OH)D within the HIV-infected group. The fact that CCA IMT, sTNFR-II, and sICAM-1 were correlated with serum 25(OH)D within the control group but not with the HIV-infected group may provide support for this, but, on the other hand, it may merely emphasize the complex interaction of vitamin D with the variety of HIV-related factors. Similarly, the regression model must be interpreted with caution given the large number of relevant variables and the small overall N.

Nevertheless, this study supports the concept that vitamin D deficiency is associated with worse CVD risk profile in HIV-infected individuals. Randomized-controlled clinical trials are needed to further explore these relationships, better account for potential confounders, and investigate the effect of vitamin D supplementation on attenuating CVD risk, especially among HIV-infected youth where an opportunity exists for disease prevention.
Acknowledgments

Sources of Support: The study was funded by an independent research grant from GlaxoSmithKline Collaborative Study Group, as well as supported by research grants to Dr. McComsey (R01HD070490) and Dr. Eckard (1K23HD069199) from the National Institutes of Health, National Institute of Child Health and Development. The funding agencies had absolutely no role in study design, data collection or analysis.

References


Pediatr Infect Dis J. Author manuscript; available in PMC 2014 November 01.


Figure 1. Percentage of HIV-infected subjects and healthy controls with vitamin D deficiency, insufficiency, and sufficiency
This figure shows the proportion of subjects by study group in each category of vitamin D status based on serum concentrations of 25(OH)D. Vitamin D deficiency is defined as 25(OH)D <20 ng/mL, vitamin D insufficiency as 25(OH)D ≥20–29 ng/mL, and optimal vitamin D status as 25(OH)D >29 ng/mL. There was no difference between groups in the proportions of subjects in each vitamin D status category (P = 0.17). The majority of subjects from both groups were in the vitamin D deficient range. One HIV-infected subject was inadvertently taking mega-doses of vitamin D and had a 25(OH)D concentration of 204 ng/mL. 25(OH)D, 25-hydroxyvitamin D
Table 1

Subjects characteristics.

<table>
<thead>
<tr>
<th></th>
<th>HIV-infected</th>
<th>Controls</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Median (Range) Unless Specified Otherwise</td>
<td>N = 30</td>
<td>N = 31</td>
</tr>
<tr>
<td>Age, years</td>
<td>12.5 (4.2–24.3)</td>
<td>10.8 (4.3–28.0)</td>
<td>0.23</td>
</tr>
<tr>
<td>Male, no. (%)</td>
<td>11 (37%)</td>
<td>14 (45%)</td>
<td>0.50</td>
</tr>
<tr>
<td>Black, no. (%)</td>
<td>25 (81%)</td>
<td>22 (73%)</td>
<td>0.50</td>
</tr>
<tr>
<td>Winter/spring blood draw</td>
<td>24 (77%)</td>
<td>19 (63%)</td>
<td>0.23</td>
</tr>
<tr>
<td>BMI (kg/m²)</td>
<td>20 (15–38)</td>
<td>19 (15–31)</td>
<td>0.31</td>
</tr>
<tr>
<td>Systolic BP (mmHg)</td>
<td>104 (88–140)</td>
<td>104 (88–126)</td>
<td>0.94</td>
</tr>
<tr>
<td>Diastolic BP (mmHg)</td>
<td>68 (48–88)</td>
<td>70 (56–82)</td>
<td>0.40</td>
</tr>
<tr>
<td>TC (mg/dL)</td>
<td>164 (106–278)</td>
<td>154 (93–222)</td>
<td>0.07</td>
</tr>
<tr>
<td>HDL (mg/dL)</td>
<td>51 (23–74)</td>
<td>55 (40–80)</td>
<td>0.12</td>
</tr>
<tr>
<td>TG (mg/dL)</td>
<td>78 (30–292)</td>
<td>45 (10–124)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>2.01 (0.18–6.89)</td>
<td>1.64 (0.34–5.39)</td>
<td>0.43</td>
</tr>
<tr>
<td>CCA IMT (mm)</td>
<td>1.00 (0.70–1.25)</td>
<td>1.00 (0.75–1.25)</td>
<td>0.75</td>
</tr>
<tr>
<td>ICA IMT (mm)</td>
<td>0.85 (0.53–1.83)</td>
<td>0.90 (0.50–1.15)</td>
<td>0.49</td>
</tr>
<tr>
<td>TNF-α (pg/ml)</td>
<td>3.65 (0.44–17.12)</td>
<td>3.55 (0.55–29.11)</td>
<td>0.70</td>
</tr>
<tr>
<td>sTNFR-I (pg/ml)</td>
<td>578 (192–6,274)</td>
<td>644 (253–6,870)</td>
<td>0.36</td>
</tr>
<tr>
<td>sTNFR-II (pg/ml)</td>
<td>673 (315–7,368)</td>
<td>570 (163–7,533)</td>
<td>0.23</td>
</tr>
<tr>
<td>hsCRP (mg/L)</td>
<td>0.59 (0.00–47.46)</td>
<td>0.05 (0.00–11.98)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>IL-6 (pg/ml)</td>
<td>3.45 (0.36–17.88)</td>
<td>2.58 (0.29–29.10)</td>
<td>0.33</td>
</tr>
<tr>
<td>sICAM-1 (ng/ml)</td>
<td>679 (215–2,406)</td>
<td>304 (44–1,061)</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>sVCAM-1 (ng/ml)</td>
<td>2,905 (395–16,661)</td>
<td>1,240 (627–7,347)</td>
<td>0.02</td>
</tr>
</tbody>
</table>

BMI, body mass index; BP, blood pressure; TC, total cholesterol; HDL, high-lipoprotein cholesterol; TG, triglycerides; HOMA-IR, homeostasis model assessment of insulin resistance; CCA, common carotid artery; IMT, intima-media thickness; ICA, internal carotid artery; TNF-α, tumor necrosis factor-α; sTNFR-I, soluble tumor necrosis factor receptor-I; sTNFR-II, soluble tumor necrosis factor receptor-II; IL-6, interleukin-6; hsCRP, high sensitivity C-reactive protein; sICAM-1, soluble intercellular adhesion molecule-1; sVCAM-1, soluble vascular cellular adhesion molecule-1
Table 2

HIV-infected subjects’ characteristics.

<table>
<thead>
<tr>
<th>Characteristic</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Median (range) unless specified</td>
<td>N = 30</td>
</tr>
<tr>
<td>CD4 cell count (no./mm$^3$)</td>
<td>896 (59–1988)</td>
</tr>
<tr>
<td>Nadir CD4 cell count (no./mm$^3$)</td>
<td>270 (0–1394)</td>
</tr>
<tr>
<td>Vertical transmission, no. (%)</td>
<td>26 (87%)</td>
</tr>
<tr>
<td>HIV-1 RNA &lt;400 copies/mL, no (%)</td>
<td>23 (79%)</td>
</tr>
<tr>
<td>Subjects on ART, no. (%)</td>
<td>27 (90%)</td>
</tr>
<tr>
<td>PI</td>
<td>17 (57%)</td>
</tr>
<tr>
<td>NNRTI</td>
<td>13 (43%)</td>
</tr>
<tr>
<td>Cumulative ART duration (mo.)</td>
<td>81 (16–215)</td>
</tr>
<tr>
<td>Cumulative NNRTI duration (mo.)</td>
<td>37 (0–114)</td>
</tr>
<tr>
<td>Cumulative PI duration (mo.)</td>
<td>53 (0–136)</td>
</tr>
</tbody>
</table>

ART, antiretroviral therapy; PI, protease inhibitors; NNRTI, non-nucleoside reverse transcriptase inhibitors
Table 3
Correlations between serum 25(OH)D and cardiovascular disease risk factors, inflammation, and HIV-related variables.

<table>
<thead>
<tr>
<th>Variable</th>
<th>HIV+</th>
<th>Controls</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>R</td>
<td>P</td>
</tr>
<tr>
<td>Age</td>
<td>−0.33</td>
<td>0.07</td>
</tr>
<tr>
<td>BMI</td>
<td>−0.41</td>
<td>0.03</td>
</tr>
<tr>
<td>HOMA-IR</td>
<td>−0.42</td>
<td>0.02</td>
</tr>
<tr>
<td>sTNFR-II</td>
<td>−0.16</td>
<td>0.40</td>
</tr>
<tr>
<td>sICAM-I</td>
<td>−0.28</td>
<td>0.53</td>
</tr>
<tr>
<td>CCA IMT</td>
<td>−0.13</td>
<td>0.34</td>
</tr>
<tr>
<td>HIV Duration</td>
<td>−0.63</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>ART Duration</td>
<td>−0.52</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>NRTI Duration</td>
<td>−0.49</td>
<td>&lt;0.01</td>
</tr>
<tr>
<td>NNRTI Duration</td>
<td>−0.45</td>
<td>0.02</td>
</tr>
</tbody>
</table>

R = Spearman Correlation Coefficient

Other variables tested but not significant: For both groups: systolic/diastolic BP, TC, LDL, HDL, TNF-α, sTNFR-I, hsCRP, IL-6, sVCAM-1; For HIV-infected group: cumulative PI duration 25(OH)D, 25-hydroxyvitamin D; BMI, body mass index; HOMA-IR, homeostasis model assessment of insulin resistance; soluble tumor necrosis factor receptor-II; sICAM-1, soluble intercellular adhesion molecule-1; CCA IMT, common carotid artery intima-media thickness; ART, antiretroviral therapy; NRTI, nucleoside reverse transcriptase inhibitors; NNRTI, non-nucleoside reverse transcriptase inhibitors; BP, blood pressure; TC, total cholesterol; HDL, high-density lipoprotein cholesterol; TG, triglycerides; TNF-α, tumor necrosis factor-α; sTNFR-I, soluble tumor necrosis factor receptor-I; hsCRP, high sensitivity C-reactive protein; IL-6, interleukin-6; sVCAM-1, soluble vascular cellular adhesion molecule-1; PI, protease inhibitor